Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., Roberts, R., Bharati, S., Stockdale, L., Gairola, S., Greenwood, B. M., Ewer, K. J., Bradley, J., Kulkarni, P. S., Shaligram, U., Hill, A. V. S.
Lancet, (2024). 403:533-544

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., Chandramohan, D., Roberts, R., Bharati, S., Stockdale, L., Gairola, S., Greenwood, B. M., Ewer, K. J., Bradley, J., Kulkarni, P. S., Shaligram, U., Hill, A. V. S.
Lancet, (2024). 403:533-544

Where do those data go? Reuse of screening results from clinical trials to estimate population prevalence of HBV infection in adults in Kilifi, Kenya.
Downs, L. O., Campbell, C., Abouyannis, M., Otiende, M., Kapulu, M., Obiero, C. W., Hamaluba, M., Ngetsa, C., Andersson, M. I., Githinji, G., Warimwe, G., Baisley, K., Scott, J. A. G., Matthews, P. C., Etyang, A.
J Virus Erad, (2023). 9:100355

Anti-merozoite antibodies induce natural killer cell effector function and are associated with immunity against malaria.
Odera, D. O., Tuju, J., Mwai, K., Nkumama, I. N., Fürle, K., Chege, T., Kimathi, R., Diehl, S., Musasia, F. K., Rosenkranz, M., Njuguna, P., Hamaluba, M., Kapulu, M. C., Frank, R., Osier, F. H. A., Abdi, A. I., Chi, P. C., de Laurent, Z., Jao, I., Kamuya, D., Kamuyu, G., Makale, J., Murungi, L., Musyoki, J., Muthui, M., Mwacharo, J., Kariuki, S., Mwanga, D., Mwongeli, J., Ndungu, F., Njue, M., Nyangweso, G., Kimani, D., Ngoi, J. M., Musembi, J., Ngoto, O., Otieno, E., Ooko, M., Shangala, J., Wambua, J., Mohammed, K. S., Omuoyo, D., Mosobo, M., Kibinge, N., Kinyanjui, S., Bejon, P., Lowe, B., Marsh, K., Marsh, V., Abebe, Y., Billingsley, P. F., Sim, B. K. L., Hoffman, S. L., James, E. R., Richie, T. L., Audi, A., Olewe, F., Oloo, J., Ongecha, J., Ongas, M. O., Koskei, N., Bull, P. C., Hodgson, S. H., Kivisi, C., Imwong, M., Murphy, S. C., Ogutu, B., Tarning, J., Winterberg, M., Williams, T. N.
Sci Transl Med, (2023). 15:eabn5993

[A global core outcome measurement set for snakebite clinical trials].
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B. K., Mwalukore, S., Alphan, H. J., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J. P., Coldiron, M. E., Gutiérrez, J. M., Habib, A. G., Harrison, R. A., Isbister, G. K., Lavonas, E. J., Martins, D., Ribeiro, I., Watson, J. A., Williams, D. J., Casewell, N. R., Walker, S. A., Lalloo, D. G.
Med Trop Sante Int, (2023). 3:mtsi.v3i3.2023.421

A long-term observational study of paediatric snakebite in Kilifi County, south-east Kenya.
Abouyannis, M., Boga, M., Amadi, D., Ouma, N., Nyaguara, A., Mturi, N., Berkley, J. A., Adetifa, I. M., Casewell, N. R., Lalloo, D. G., Hamaluba, M.
PLoS Negl Trop Dis, (2023). 17:e0010987

Targeted amplicon deep sequencing of ama1 and mdr1 to track within-host P. falciparum diversity throughout treatment in a clinical drug trial.
Wamae, K., Ndwiga, L., Kharabora, O., Kimenyi, K., Osoti, V., de Laurent, Z., Wambua, J., Musyoki, J., Ngetsa, C., Kalume, P., Mwambingu, G., Hamaluba, M., van der Pluijm, R., Dondorp, A. M., Bailey, J., Juliano, J., Bejon, P., Ochola-Oyier, L.
Wellcome Open Res, (2022). 7:95

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi, D., Juan-Giner, A., Orindi, B., Grantz, K. H., Bob, N. S., Cheruiyot, S., Hamaluba, M., Kamau, N., Fall, G., Dia, M., Mosobo, M., Moki, F., Kiogora, K., Chirro, O., Thiong'o, A., Mwendwa, J., Guantai, A., Karanja, H. K., Gitonga, J., Mugo, D., Ramko, K., Faye, O., Sanders, E. J., Grais, R. F., Bejon, P., Warimwe, G. M.
Lancet Infect Dis, (2023). S1473-3099:00114-7

A global core outcome measurement set for snakebite clinical trials.
Abouyannis, M., Esmail, H., Hamaluba, M., Ngama, M., Mwangudzah, H., Mumba, N., Yeri, B. K., Mwalukore, S., Alphan, H. J., Aggarwal, D., Alcoba, G., Cammack, N., Chippaux, J. P., Coldiron, M. E., Gutierrez, J. M., Habib, A. G., Harrison, R. A., Isbister, G. K., Lavonas, E. J., Martins, D., Ribeiro, I., Watson, J. A., Williams, D. J., Casewell, N. R., Walker, S. A., Lalloo, D. G., Snakebite Global Core Outcome Set Study, Group
Lancet Glob Health, (2023). 11:e296-e300

Phagocytosis of Plasmodium falciparum ring-stage parasites predicts protection against malaria.
Musasia, F. K., Nkumama, I. N., Frank, R., Kipkemboi, V., Schneider, M., Mwai, K., Odera, D. O., Rosenkranz, M., Furle, K., Kimani, D., Tuju, J., Njuguna, P., Hamaluba, M., Kapulu, M. C., Wardemann, H., CHMI-SIKA Study Team., Osier, F. H. A.
Nat Commun, (2022). 13:4098